Cuba’s COVID Vaccine Could Break Big Pharma’s IP Shakedown | WHAT REALLY HAPPENED X-Frame-Options: DENY X-Frame-Options: SAMEORIGIN

Cuba’s COVID Vaccine Could Break Big Pharma’s IP Shakedown

The worldwide Covid vaccine rollout has gone anything but smoothly, with only a handful of countries able to immunize even 10% of their populations yet with a first dose. Two primary causes of this have been rich nations hoarding precious doses and their refusal to waive the intellectual property rights to their creations, both of which have led to massive shortages across the world, particularly in the global south.

These practices have been denounced by charities and human rights groups alike. Oxfam expressed its dismay that, as a result of copyright rules, three of the largest pharmaceutical companies on the planet are doing nothing to produce vaccines as they have not secured the rights to do so, even as up to 10,000 people die daily from COVID-19. Human Rights Watch has supported a proposal led by India and South Africa that Western governments should waive any restrictions on the production of lifesaving vaccines. But there appears to be little prospect of that happening soon.

Breaking Big Pharma

One spot of hope is coming from Cuba, however. The country’s self-produced Soberana 02 (Sovereign 2 in English) vaccine begins its third phase of trials today, a move that will see it tested on as many as 150,000 people in just a few weeks. Stage three trials are the final step before mass rollout.